Advertisement

ALC

Alcon Inc.

Healthcare · USD

Set alert

Price alert · ALC

All alert types
71.45 USD +0.32 +0.45%
As of Oct 30, 2026 Extended hours 71.45 0.00%
Bid
71.46 × 400
Ask
71.50 × 300
71.27 Day range 72.67
62.02 52-week range 87.18
YTD
-9.34%
1 year
-3.78%
Open
72.34
Prev close
71.13
Mkt cap
34.54B
Vol
1.61M
Avg vol
1.69M
EPS
1.32
P/E
54.13
Div yield
0.51%
More statistics
Low
71.27
High
72.67
Forward P/E
18.08
Beta
0.73
Short ratio
10.62
Inst. own
62.56%
Dividend
0.36
Ex-div date
May 5, 2026
Earnings
Nov 10, 2026
50-d avg
67.67
200-d avg
71.99
1y target
81.98

5D chart

Chart tools
Interval
ALC five-day price chart68.869.570.170.771.3Oct 23Oct 26Oct 27Oct 28Oct 29

Key statistics

Market cap
34.55B
Enterprise value
38.23B
Trailing P/E
54.14
Forward P/E
18.08
PEG ratio
1.28
Price / sales
3.18
Price / book
1.60
EPS (TTM)
1.32
Beta
0.73
Dividend yield
0.51%
Payout ratio
26.56%
Profit margin
5.92%
Revenue (TTM)
10.86B
Revenue growth
8.70%
Free cash flow
1.27B
Total cash
1.46B
Total debt
5.30B
Return on equity
2.94%
Shares outstanding
483.40M
Short % of float
0.00%
50-day average
67.67
200-day average
71.99

Analyst view

Consensus: buy

Buy
Price target (mean) 81.98 +14.7% upside
Target (low)
62.00
Target (mean)
81.98
Target (high)
103.00
Ratings (0m) 27 21 buy · 5 hold · 1 sell
  • Strong buy4
  • Buy17
  • Hold5
  • Sell0
  • Strong sell1

Next earnings

Nov 10, 2026

Expected Nov 10, 2026. Consensus EPS estimate 0.89001.

Earnings history

Financials — quick view

All financials
ALC Revenue — quarterly 2.82B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALC Net income — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALC EPS — quarterly 0.00
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ALC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 10, 2026Sep 30, 20260.89———
Aug 10, 2026Jun 30, 20260.770.84+0.07+9.09%
May 5, 2026Mar 31, 20260.800.85+0.05+6.25%
Feb 24, 2026Dec 31, 20250.790.78-0.01-1.27%
Nov 11, 2025Sep 30, 20250.770.79+0.02+2.60%
Aug 19, 2025Jun 30, 20250.710.76+0.05+7.04%

Upgrades / downgrades

ALC analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026KeybancmainOverweightOverweight
Oct 21, 2026NeedhamreitBuyBuy
Oct 12, 2026BTIGmainBuyBuy
Oct 7, 2026Barclaysinit—Equal-Weight
Sep 22, 2026JefferiesmainBuyBuy
Sep 15, 2026NeedhamreitBuyBuy

About Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Switzerland
Website
alcon.com

News

Your note

Sign in to keep a note on ALC — it syncs with the Stock Master app.

Institution ownership

ALC institution ownership
Holder% heldSharesValueReported
Vanguard Capital Management LLC2.95%14,749,5821.05BJun 29, 2026
Bank Of New York Mellon Corporation2.61%13,057,962933.25MJun 29, 2026
NORGES BANK2.20%10,976,697784.50MJun 29, 2026
Invesco Ltd.2.08%10,380,332741.88MJun 29, 2026
Aristotle Capital Management, LLC2.00%9,979,069713.20MJun 29, 2026
AKO Capital LLP1.94%9,683,004692.04MJun 29, 2026

Fund ownership

ALC fund ownership
Holder% heldSharesValueReported
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1.44%7,175,218512.81MJul 30, 2026
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund0.95%4,758,876340.12MJun 29, 2026
iShares Trust-iShares Core MSCI EAFE ETF0.75%3,735,153266.95MSep 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund0.66%3,283,650234.68MAug 30, 2026
VANGUARD WINDSOR FUNDS-Vanguard Windsor II Fund0.58%2,918,000208.55MJul 30, 2026
MFS SERIES TRUST X-MFS International Intrinsic Equity Fund0.48%2,417,516172.78MAug 30, 2026
Advertisement